|
From Science:
Lessons in immune surveillance:
Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1
The glycine-alanine repeat domain (GAr) of Epstein-Barr virus–encoded nuclear antigen 1 (EBNA1) prevents MHC class I–restricted presentation of EBNA1 epitopes to cytotoxic T cells, an effect previously attributed to the ability of GAr to inhibit its own proteasomal degradation. Yin et al. show, both in vitro and in vivo, that GAr also inhibits mRNA translation of EBNA1 in cis and that this effect can be distinguished from its effect on proteasomal degradation. Thus, by minimizing translation of the EBNA1 transcript, cells expressing EBNA1 avoid CTL cell recognition.
— By Yili Yin, Bénédicte Manoury, Robin Fåhraeus
[About AIDScience articles] [See recent AIDScience articles]
Hot News:
Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy
Although there has been a proportional increase in AIDS dementia complex (ADC) at AIDS diagnosis, survival following ADC has improved markedly in the era of HAART. AIDS 17(10), 1539, 4 July 2003. Commentary from the CDC HIV/STD/TB Prevention News Update.
A tailored minimal self-help intervention to promote condom use in young women
The study evaluated the efficacy of a theory-based tailored minimal self-help intervention to increase condom use among young women at risk for HIV and STDs. AIDS 17(10), 1547, 4 July 2003. Commentary from the CDC HIV/STD/TB Prevention News Update.
Highly exposed seronegative individuals: what kind of immunity?
Immunity in individuals who have been exposed to HIV-1 but have remained seronegative (ES) may hold clues for HIV vaccine design. A new study in a group of 46 ES men suggests that HIV-1-specific, IFN-{gamma}-secreting T cells are unlikely to substantially contribute to resistance against infection in most subjects. Journal of Immunology 171, 2671, 1 September 2003.
From Medscape: Tyrosine-sulfated antibodies critical in controlling HIV infection
Many critical antibodies that target the HIV-1 envelope glycoprotein gp120 contain sulfated tyrosine moieties at their antigen binding sites, according to a report in the July 25th issue of Cell (Medscape requires one-time free registration). See PubMed abstract here.
|
